Meeting slides
Suggested Readings

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, et al. J Hepatol. 2018;68(4):672-681.

Non-alcoholic fatty liver disease: an expanded review.

Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.

NAFLD: a multisystem disease.

Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.

Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.

Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.

Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis.

Dulai PS, et al. Hepatology. 2017;65(5):1557-1565.

Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.

Dyson JK, et al. J Clin Pathol. 2013;66(12):1033-1045.

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Feld JJ, et al. N Engl J Med. 2014;370(17):1594-1603.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, et al. Hepatology. 2018;67(5):1754-1767.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, et al. Lancet Gastroenterol Hepatol. 2018;3(3):153-161.

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.

Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.

Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

Lee MH, et al. Hepatology. 2013;58(2):546-554.

Hepatitis B cure: from discovery to regulatory approval.

Lok AS, et al. Hepatology. 2017;66(4):1296-1313.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.

Loomba R, et al. Hepatology. 2018;67(2):549-559.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.

Improved bone and renal safety at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB).

Pan CQ, et al. Hepatology. 2017; 66(suppl 1):482A.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Papatheodoridis GV, et al. Hepatology. 2017;66(5):1444-1453.

The therapeutic landscape of non-alcoholic steatohepatitis.

Perazzo H, Dufour JF. Liver Int. 2017;37(5):634-647.

Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.

Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study.

Ratziu V, et al. J Hepatol. 2018;68(suppl 1):S1-S2.

Management of NAFLD: a stage-based approach.

Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.

Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Spengler EK, Loomba R. Mayo Clin Proc. 2015;90(9):1233-1246.

The performance of vibration controlled transient elastography in a US cohort of patients with non-alcoholic fatty liver disease.

Tapper EB, et al. Am J Gastroenterol. 2016;111(5):677-684.

Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.

Challenges to a cure for HBV infection.

Testoni B, et al. Semin Liver Dis. 2017;37(3):231-242.

Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland.

Tyrfingsson T, et al. J Hepatol. 2018;68(suppl 1):S52

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.

Wong VW, et al. Hepatology. 2010;51(2):454-462.

Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence, and outcomes.

Younossi ZM, et al. Hepatology. 2016;64(1):73-84.

Linked Resources

Clinical Practice Guidelines

Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.

American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2018;67(10):1477-1492.

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.

Chalasani N, et al. Hepatology. 2018;67(1):328-357.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

European Association for the Study of the Liver. J Hepatol. 2017;67(2):370-398.

EASL recommendations on treatment of hepatitis C 2018.

European Association for the Study of the Liver (EASL). J Hepatol. 2018;69(2):461-511.

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). J Hepatol. 2016;64(6):1388-1402.

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Terrault NA, et al. Hepatology. 2018;67(4):1560-1599.

Clinical Resources

Histological Scoring System for Nonalcoholic Fatty Liver Disease.

Transplant Pathology Internet Services, 2009.

MELD Score (Model for End-Stage Liver Disease) (12 years and older).

MD+CALC online calculator, 2016.

NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.

MD+CALC online calculator.

Patient Resources

American College of Gastroenterology (ACG) Patient Education and Resource Center.

The ACG website provides a basic overview of chronic liver disease that includes patient-centered podcasts.

American Liver Foundation.

The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.

Centers for Disease Control and Prevention (CDC).

The CDC provides an overview of all forms of viral hepatitis and how to get tested for both hepatitis C virus (HCV) and hepatitis B virus (HBV).

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.

The NIDDK website for NAFLD and nonalcoholic steatohepatitis (NASH) provides comprehensive patient-centered information and resources, including an overview of clinical trial participation.

Related activities
1.50 CME

Clinical Issues™ in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Faculty: Stephen A. Harrison, MD, FAASLD; Quentin M. Anstee, PhD, FRCP; W. Ray Kim, MD; Mark S. Sulkowski, MD
Release: 02/22/2019
Expiration: 02/22/2020